Hello guys, Welcome to Africa's Largest Video Search Engine, and you are watching Don’t Count Yourself Out: Karen’s Cancer Immunotherapy Story. and this video is uploaded by Cancer Research Institute at 2021-06-03T06:00:15-07:00. We are just promoting this video only for entertainment and educational purpose only. I hop you like our Video Search Engine. [WzM18PwU2T4]
| Name | Don’t Count Yourself Out: Karen’s Cancer Immunotherapy Story |
| Video Uploader | Video From Cancer Research Institute |
| Upload Date | This Video Uploaded At 03-06-2021 13:00:15 |
| Video Discription | Karen was given eight months to live after diagnosis with metastatic triple-negative breast cancer, but she researched and found a clinical trial combining two immunotherapies, bempegaldesleukin (BEMPEG) and nivolumab (Opdivo), that saved her life. #CIM21 #Immune2Cancer #CancerStory Following surgery and chemotherapy for stage 1 triple-negative breast cancer, Karen took charge of her cancer narrative by researching other treatment options and talking to experts during a brief period of remission. When her cancer returned in 2017—this time metastatic—she was facing a life expectancy of 18 to 24 months, but she was prepared to try something new. She enrolled as the first patient in a phase 1 trial at NYU Langone’s Perlmutter Cancer Center combining two immunotherapies: bempegaldesleukin (BEMPEG; NKTR-214) and nivolumab (Opdivo®). Her first CT scan, after eight weeks of immunotherapy, revealed a 72% reduction in tumors. In June 2020, Karen’s oncologist declared her “an official complete responder.” Karen is a CRI ImmunoAdvocate and passionate about advocating for health equity and sharing her story to inspire other patients. https://www.cancerresearch.org/patients/immunocommunity/featured-stories/karenp This video is part of the 9th Annual Cancer Immunotherapy Month™ in June 2021, hosted by the Cancer Research Institute. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let's fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. https://www.cancerresearch.org/june #Immune2Cancer Immunotherapy patient stories are part of the Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law. [WzM18PwU2T4] |
| Category | Nonprofits & Activism |
| Tags | Cancer Research Institute | cancer | immunotherapy | cancer research | cancer treatment | cancer clinical trials | metastatic cancer | breast cancer | triple-negative breast cancer | NYU Langone Perlmutter cancer center | TNBC | Karen Peterson | African American | cancer disparities | tumor-infiltrating lymphocytes | bempegaldesleukin | BEMPEG | nivolumab | Opdivo | PD-1 inhibitor | IL-2 | cancer story |
